Archon Partners’s Merck MRK Stock Holding History

Archon Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-82,500	Closed	-$8.49M	–	44
2023 Q3	$8.49M	Hold	82,500	–	–	1.33%	28
2023 Q2	$9.52M	Hold	82,500	–	–	1.42%	26
2023 Q1	$8.78M	Hold	82,500	–	–	1.46%	25
2022 Q4	$9.15M	Buy	+82,500	New	+$8.43M	1.65%	25
2013 Q3	–	Sell	-155,104	Closed	-$6.88M	–	68
2013 Q2	$6.88M	Buy	+155,104	New	+$6.93M	2.35%	24

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Archon Partners's MRK Position: Q4 2023 in Review

Archon Partners sold out of Merck (MRK) in Q4 2023, closing a stake of 82,500 shares — an estimated $8.49M sold.

Archon Partners first reported a position in MRK in Q2 2013 and held it in 5 quarters. The position peaked at $9.52M in Q2 2023. 3,434 funds tracked by Wall St. Rank hold MRK as of Q4 2023.

Archon Partners reported no remaining Merck position as of Q4 2023 after selling out during the quarter.
Archon Partners sold 82,500 Merck shares in Q4 2023, an estimated $8.49M.
Archon Partners first reported a position in Merck in Q2 2013 and held it in 5 quarters.
Archon Partners's Merck position peaked at $9.52M in Q2 2023.
3,434 funds tracked by Wall St. Rank held Merck as of Q4 2023.

Based on Archon Partners's 13F filing for Q4 2023, filed 14 Feb 2024.